{"id":32742,"date":"2025-07-30T08:45:49","date_gmt":"2025-07-30T08:45:49","guid":{"rendered":"https:\/\/ibima.eu\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\/"},"modified":"2025-07-30T08:45:49","modified_gmt":"2025-07-30T08:45:49","slug":"estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\/","title":{"rendered":"Estudio en fase II\/III aleatorizado, doble ciego, controlado con palivizumab para evaluar la seguridad de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en ni\u00f1os de alto riesgo (MEDLEY)"},"content":{"rendered":"<p>PILAR CARO AGUILERA &#8211; ENSAYO CLINICO COMERCIAL &#8211; III &#8211; MEDLMMUNE LLC<\/p>","protected":false},"excerpt":{"rendered":"<p>PILAR CARO AGUILERA &#8211; ENSAYO CLINICO COMERCIAL &#8211; III &#8211; MEDLMMUNE LLC<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2270],"tags":[],"class_list":["post-32742","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-a-19-ensayos-clinicos"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Estudio en fase II\/III aleatorizado, doble ciego, controlado con palivizumab para evaluar la seguridad de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en ni\u00f1os de alto riesgo (MEDLEY) - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/en\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estudio en fase II\/III aleatorizado, doble ciego, controlado con palivizumab para evaluar la seguridad de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en ni\u00f1os de alto riesgo (MEDLEY) - Ibima\" \/>\n<meta property=\"og:description\" content=\"PILAR CARO AGUILERA &#8211; ENSAYO CLINICO COMERCIAL &#8211; III &#8211; MEDLMMUNE LLC\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/en\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:45:49+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"Estudio en fase II\\\/III aleatorizado, doble ciego, controlado con palivizumab para evaluar la seguridad de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en ni\u00f1os de alto riesgo (MEDLEY)\",\"datePublished\":\"2025-07-30T08:45:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\\\/\"},\"wordCount\":48,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - A-19\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\\\/\",\"name\":\"Estudio en fase II\\\/III aleatorizado, doble ciego, controlado con palivizumab para evaluar la seguridad de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en ni\u00f1os de alto riesgo (MEDLEY) - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:45:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estudio en fase II\\\/III aleatorizado, doble ciego, controlado con palivizumab para evaluar la seguridad de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en ni\u00f1os de alto riesgo (MEDLEY)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/en\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estudio en fase II\/III aleatorizado, doble ciego, controlado con palivizumab para evaluar la seguridad de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en ni\u00f1os de alto riesgo (MEDLEY) - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/en\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\/","og_locale":"en_GB","og_type":"article","og_title":"Estudio en fase II\/III aleatorizado, doble ciego, controlado con palivizumab para evaluar la seguridad de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en ni\u00f1os de alto riesgo (MEDLEY) - Ibima","og_description":"PILAR CARO AGUILERA &#8211; ENSAYO CLINICO COMERCIAL &#8211; III &#8211; MEDLMMUNE LLC","og_url":"https:\/\/ibima.eu\/en\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:45:49+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"Estudio en fase II\/III aleatorizado, doble ciego, controlado con palivizumab para evaluar la seguridad de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en ni\u00f1os de alto riesgo (MEDLEY)","datePublished":"2025-07-30T08:45:49+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\/"},"wordCount":48,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - A-19"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\/","url":"https:\/\/ibima.eu\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\/","name":"Estudio en fase II\/III aleatorizado, doble ciego, controlado con palivizumab para evaluar la seguridad de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en ni\u00f1os de alto riesgo (MEDLEY) - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:45:49+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/estudio-en-fase-ii-iii-aleatorizado-doble-ciego-controlado-con-palivizumab-para-evaluar-la-seguridad-de-medi8897-un-anticuerpo-monoclonal-con-una-semivida-prolongada-frente-al-virus-respiratorio-si-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Estudio en fase II\/III aleatorizado, doble ciego, controlado con palivizumab para evaluar la seguridad de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en ni\u00f1os de alto riesgo (MEDLEY)"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/en\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/32742","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/comments?post=32742"}],"version-history":[{"count":3,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/32742\/revisions"}],"predecessor-version":[{"id":55810,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/32742\/revisions\/55810"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media?parent=32742"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/categories?post=32742"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/tags?post=32742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}